JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
Loading...